The Medicines Patent Pool’s work depends on partnerships with stakeholders in the field of HIV, hepatitis C and tuberculosis, and its partnerships with patent holding companies are critical to its success.
Following the announcement of MPP’s expansion into hepatitis C and tuberculosis treatment approved by its funder UNTAID in November 2015, the Medicines Patent Pool signed a licensing agreement with Bristol-Myers Squibb (BMS) for hepatitis C medicines daclatasvir (DCV) allowing generic manufacturer to develop and distribute daclatasvir in 112 low- and middle-income countries. The MPP has opened negotiations with the Egyptian drug manufacturer Pharco Pharmaceuticals for the hepatitis C drug candidate ravidasvir.
The MPP also has begun negotiations with a research-based university for sutezolid, a promising treatment for tuberculosis.
The MPP has signed licensing agreements with AbbVie, Bristol-Myers Squibb, Gilead Sciences, Johns Hopkins University, MSD (Merck & Co in the USA and Canada), Roche, ViiV Healthcare [a joint venture of GlaxoSmithKline, Pfizer and Shionogi], the University of Liverpool and the US National Institutes of Health.
The Medicines Patent Pool has also sub-licensed to generic manufacturers, who are already beginning to produce and supply HIV medicines at a lower cost. As of November 2016, the MPP had signed sub-licensing agreements with fifteen generic manufacturers: Aurobindo Pharma Limited, Beximco, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Huahai Pharmaceutical, Laurus Labs, Lupin, Micro Labs, Mylan, Natco, Sandoz, Strides Arcolab and Zydus Cadila.
The MPP looks forward to continuing dialogue with all relevant patent holders and eligible generic manufacturers and product development partnerships to increase access to medicines for people living in developing countries.
Patent Holder Engagement